UK markets open in 3 hours 28 minutes

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.08+0.14 (+2.83%)
At close: 04:00PM EDT
5.18 +0.10 (+1.97%)
After hours: 06:41PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 296.15M
Enterprise value 152.67M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.79
Price/book (mrq)1.80
Enterprise value/revenue 3.65
Enterprise value/EBITDA -1.75

Trading information

Stock price history

Beta (5Y monthly) 0.98
52-week change 3-58.19%
S&P500 52-week change 3-11.09%
52-week high 313.97
52-week low 34.85
50-day moving average 39.21
200-day moving average 39.94

Share statistics

Avg vol (3-month) 3599.69k
Avg vol (10-day) 3641.62k
Shares outstanding 553.94M
Implied shares outstanding 6N/A
Float 845.27M
% held by insiders 116.05%
% held by institutions 165.46%
Shares short (14 Mar 2023) 45.14M
Short ratio (14 Mar 2023) 45.54
Short % of float (14 Mar 2023) 413.47%
Short % of shares outstanding (14 Mar 2023) 49.53%
Shares short (prior month 14 Feb 2023) 45.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022

Profitability

Profit margin -204.16%
Operating margin (ttm)-209.08%

Management effectiveness

Return on assets (ttm)-25.49%
Return on equity (ttm)-44.25%

Income statement

Revenue (ttm)41.87M
Revenue per share (ttm)0.78
Quarterly revenue growth (yoy)297.20%
Gross profit (ttm)-56.14M
EBITDA -87.29M
Net income avi to common (ttm)-85.47M
Diluted EPS (ttm)-1.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)145.4M
Total cash per share (mrq)2.69
Total debt (mrq)1.92M
Total debt/equity (mrq)1.21
Current ratio (mrq)7.20
Book value per share (mrq)2.95

Cash flow statement

Operating cash flow (ttm)-78.73M
Levered free cash flow (ttm)-46.93M